The Liquid Biopsy Market is projected to grow at a significant pace reaching a CAGR of approximately 13.7%, over the forecast period of 2022–2030, despite a considerable fall in product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.
In a recent research report by Reports Insight Consulting Pvt. Ltd, the Liquid Biopsy Market is expected to surpass USD 24.14 billion by the year 2030, from USD 7.60 billion in 2021.
Liquid biopsy is a test performed on a blood sample extracted from cancer cells circulating in the blood. A liquid biopsy test is employed to find cancer at an early stage and identify the best treatment option or to find out how well treatment is working. The test also helps surgeons or doctors to understand what kind of molecular changes are taking place in a tumor.
The exosomes/Microvesicles segment is projected to grow at the fastest CAGR during the forecast period. Owing to the rising adoption of exosomes as a liquid biopsy in the introduction of novel products coupled with oncology clinical diagnosis.
Asia-Pacific is expected to develop at the fastest CAGR throughout the research period, owing to an increase in healthcare spending, an increase in per capita income, and improvements in healthcare infrastructure. Furthermore, Europe is predicted to obtain the second biggest market share throughout the projection period due to the region's infrastructural development and increased cancer occurrences.
The study is consolidated into major segments and further into sub-segments, such as by technology (multi-gene-parallel analysis (NGS), single gene analysis (PCR microarrays), sample type (blood sample-based, others) biomarker (circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins), to forecast the liquid biopsy market size by value; also includes the analysis of past market dynamics from 2016 – 2021, considering 2021 as the base year.
Lastly, the report includes a regional analysis and country analysis with the latest trends, along with the major key players including QIAGEN; Myriad Genetics, Inc; BIOCEPT, Inc; Guardant Health, Inc; F. Hoffmann-La Roche Ltd; Illumina, Inc; Angle plc; Oncimmune; Thermo Fisher Scientific, Inc.; Lucence health Inc.; Freenome holdings, Inc.; Epigenomics AG
Contact us:
